Blackmores Limited Stocks

A$ 0Last Updated 23.03.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

A$ 1.29B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Blackmores Limited develops, sells, and markets natural health products for humans and animals in Australia, New Zealand, Asia, China, and India. The company offers vitamins, and herbal and mineral nutritional supplements. It also provides products for various conditions related to arthritis, joints, bones, and muscles; brain health; cold, flu, and immunity; digestive health; energy and exercise; everyday health; and eye health. In addition, the company offers products in the areas of fish and nutritional oils; heart and circulation; infant nutrition; kids health; men's health; multivitamins; nails, hair, and skin; pet health; probiotics; pregnancy and preconception; stress relief and sleep support; weight management; wellbeing management; and women's health. It provides its products through retail and online channels. The company was founded in 1930 and is headquartered in Sydney, Australia.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks